A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggr...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2019
Main Authors: Flørenes, Vivi Ann, Flem-Karlsen, Karine, McFadden, Erin, Bergheim, Inger Riise, Nygaard, Vigdis, Nygård, Vegard Mokleiv, Farstad, Inger Nina, Øy, Geir Frode, Emilsen, Elisabeth, Fleten, Karianne Giller, Ree, Anne Hansen, Flatmark, Kjersti, Gullestad, Hans Petter, Hermann, Robert, Ryder, Truls, Wernhoff, Patrik, Mælandsmo, Gunhild Mari
Format: Article
Language:Norwegian
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Translational oncology
container_volume
creator Flørenes, Vivi Ann
Flem-Karlsen, Karine
McFadden, Erin
Bergheim, Inger Riise
Nygaard, Vigdis
Nygård, Vegard Mokleiv
Farstad, Inger Nina
Øy, Geir Frode
Emilsen, Elisabeth
Fleten, Karianne Giller
Ree, Anne Hansen
Flatmark, Kjersti
Gullestad, Hans Petter
Hermann, Robert
Ryder, Truls
Wernhoff, Patrik
Mælandsmo, Gunhild Mari
description Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate therapy response. A strong association between Vemurafenib response and BRAF mutation status was achieved (P 
format article
fullrecord <record><control><sourceid>cristin</sourceid><recordid>TN_cdi_cristin_nora_10852_73986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10852_73986</sourcerecordid><originalsourceid>FETCH-cristin_nora_10852_739863</originalsourceid><addsrcrecordid>eNqFjc1KA1EMhS-iYP15BvMCA_NDx86yloqC7cIObofUiZ3ITG65SavzQj6nF3ThTgjnhHC-kxM3yaqiTKZ5UZz-2c_dhep7mpZZlecT9zWHugtEScsDibIX7GH5CS989FFwyz3bCHNVHOGZjoS9AsLGgpcdLHwI1KNFDO7IPogkhnTvRQnMQ41hR0YtPErHWzYfIiwtrA72A22iHxRYYBV7xA8IT-Ow72DtW4o3Q41DeuXO3uJnuv71S3dzv6wXD8lrYDWWRnzAJktn07y5LapZWfyf-AYc7Vvx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases</title><source>Open Access: PubMed Central</source><source>NORA - Norwegian Open Research Archives</source><source>ScienceDirect (Online service)</source><creator>Flørenes, Vivi Ann ; Flem-Karlsen, Karine ; McFadden, Erin ; Bergheim, Inger Riise ; Nygaard, Vigdis ; Nygård, Vegard Mokleiv ; Farstad, Inger Nina ; Øy, Geir Frode ; Emilsen, Elisabeth ; Fleten, Karianne Giller ; Ree, Anne Hansen ; Flatmark, Kjersti ; Gullestad, Hans Petter ; Hermann, Robert ; Ryder, Truls ; Wernhoff, Patrik ; Mælandsmo, Gunhild Mari</creator><creatorcontrib>Flørenes, Vivi Ann ; Flem-Karlsen, Karine ; McFadden, Erin ; Bergheim, Inger Riise ; Nygaard, Vigdis ; Nygård, Vegard Mokleiv ; Farstad, Inger Nina ; Øy, Geir Frode ; Emilsen, Elisabeth ; Fleten, Karianne Giller ; Ree, Anne Hansen ; Flatmark, Kjersti ; Gullestad, Hans Petter ; Hermann, Robert ; Ryder, Truls ; Wernhoff, Patrik ; Mælandsmo, Gunhild Mari</creatorcontrib><description>Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate therapy response. A strong association between Vemurafenib response and BRAF mutation status was achieved (P &lt; .0001), while enhanced viability was seen in some NRAS mutated tumors. BRAF and NRAS mutated tumors responded comparably to the MEK inhibitor Cobimetinib. Based on the ex vivo results, two tumors diagnosed as BRAF wild-type by routine pathology examinations had to be re-evaluated; one was subsequently found to have a complex V600E mutation, the other a double BRAF mutation (V600E/K601 N). No BRAF inhibitor resistance mechanisms were identified, but PIK3CA and NF1 mutations were identified in two highly responsive tumors. Concordance between ex vivo drug responses using tissue from PDXs and corresponding patient tumors demonstrate that PDX models represent an indefinite source of tumor material that may allow ex vivo evaluation of numerous drugs and combinations, as well as studies of underlying molecular mechanisms. In conclusion, we have established a rapid and low cost ex vivo drug efficacy assay applicable on tumor tissue from patient biopsies. The 3D/spheroid format, limiting the influence from normal adjacent cells and allowing assessment of drug sensitivity to numerous drugs in one week, confirms its potential as a supplement to guide clinical decision, in particular in identifying non-responding patients.</description><identifier>ISSN: 1936-5233</identifier><identifier>EISSN: 1936-5233</identifier><language>nor</language><publisher>Translational Oncology, University of Michigan Medical Center, Ann Arbor, MI</publisher><ispartof>Translational oncology, 2019</ispartof><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,4024,26567</link.rule.ids></links><search><creatorcontrib>Flørenes, Vivi Ann</creatorcontrib><creatorcontrib>Flem-Karlsen, Karine</creatorcontrib><creatorcontrib>McFadden, Erin</creatorcontrib><creatorcontrib>Bergheim, Inger Riise</creatorcontrib><creatorcontrib>Nygaard, Vigdis</creatorcontrib><creatorcontrib>Nygård, Vegard Mokleiv</creatorcontrib><creatorcontrib>Farstad, Inger Nina</creatorcontrib><creatorcontrib>Øy, Geir Frode</creatorcontrib><creatorcontrib>Emilsen, Elisabeth</creatorcontrib><creatorcontrib>Fleten, Karianne Giller</creatorcontrib><creatorcontrib>Ree, Anne Hansen</creatorcontrib><creatorcontrib>Flatmark, Kjersti</creatorcontrib><creatorcontrib>Gullestad, Hans Petter</creatorcontrib><creatorcontrib>Hermann, Robert</creatorcontrib><creatorcontrib>Ryder, Truls</creatorcontrib><creatorcontrib>Wernhoff, Patrik</creatorcontrib><creatorcontrib>Mælandsmo, Gunhild Mari</creatorcontrib><title>A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases</title><title>Translational oncology</title><description>Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate therapy response. A strong association between Vemurafenib response and BRAF mutation status was achieved (P &lt; .0001), while enhanced viability was seen in some NRAS mutated tumors. BRAF and NRAS mutated tumors responded comparably to the MEK inhibitor Cobimetinib. Based on the ex vivo results, two tumors diagnosed as BRAF wild-type by routine pathology examinations had to be re-evaluated; one was subsequently found to have a complex V600E mutation, the other a double BRAF mutation (V600E/K601 N). No BRAF inhibitor resistance mechanisms were identified, but PIK3CA and NF1 mutations were identified in two highly responsive tumors. Concordance between ex vivo drug responses using tissue from PDXs and corresponding patient tumors demonstrate that PDX models represent an indefinite source of tumor material that may allow ex vivo evaluation of numerous drugs and combinations, as well as studies of underlying molecular mechanisms. In conclusion, we have established a rapid and low cost ex vivo drug efficacy assay applicable on tumor tissue from patient biopsies. The 3D/spheroid format, limiting the influence from normal adjacent cells and allowing assessment of drug sensitivity to numerous drugs in one week, confirms its potential as a supplement to guide clinical decision, in particular in identifying non-responding patients.</description><issn>1936-5233</issn><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>3HK</sourceid><recordid>eNqFjc1KA1EMhS-iYP15BvMCA_NDx86yloqC7cIObofUiZ3ITG65SavzQj6nF3ThTgjnhHC-kxM3yaqiTKZ5UZz-2c_dhep7mpZZlecT9zWHugtEScsDibIX7GH5CS989FFwyz3bCHNVHOGZjoS9AsLGgpcdLHwI1KNFDO7IPogkhnTvRQnMQ41hR0YtPErHWzYfIiwtrA72A22iHxRYYBV7xA8IT-Ow72DtW4o3Q41DeuXO3uJnuv71S3dzv6wXD8lrYDWWRnzAJktn07y5LapZWfyf-AYc7Vvx</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Flørenes, Vivi Ann</creator><creator>Flem-Karlsen, Karine</creator><creator>McFadden, Erin</creator><creator>Bergheim, Inger Riise</creator><creator>Nygaard, Vigdis</creator><creator>Nygård, Vegard Mokleiv</creator><creator>Farstad, Inger Nina</creator><creator>Øy, Geir Frode</creator><creator>Emilsen, Elisabeth</creator><creator>Fleten, Karianne Giller</creator><creator>Ree, Anne Hansen</creator><creator>Flatmark, Kjersti</creator><creator>Gullestad, Hans Petter</creator><creator>Hermann, Robert</creator><creator>Ryder, Truls</creator><creator>Wernhoff, Patrik</creator><creator>Mælandsmo, Gunhild Mari</creator><general>Translational Oncology, University of Michigan Medical Center, Ann Arbor, MI</general><scope>3HK</scope></search><sort><creationdate>2019</creationdate><title>A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases</title><author>Flørenes, Vivi Ann ; Flem-Karlsen, Karine ; McFadden, Erin ; Bergheim, Inger Riise ; Nygaard, Vigdis ; Nygård, Vegard Mokleiv ; Farstad, Inger Nina ; Øy, Geir Frode ; Emilsen, Elisabeth ; Fleten, Karianne Giller ; Ree, Anne Hansen ; Flatmark, Kjersti ; Gullestad, Hans Petter ; Hermann, Robert ; Ryder, Truls ; Wernhoff, Patrik ; Mælandsmo, Gunhild Mari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-cristin_nora_10852_739863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>nor</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flørenes, Vivi Ann</creatorcontrib><creatorcontrib>Flem-Karlsen, Karine</creatorcontrib><creatorcontrib>McFadden, Erin</creatorcontrib><creatorcontrib>Bergheim, Inger Riise</creatorcontrib><creatorcontrib>Nygaard, Vigdis</creatorcontrib><creatorcontrib>Nygård, Vegard Mokleiv</creatorcontrib><creatorcontrib>Farstad, Inger Nina</creatorcontrib><creatorcontrib>Øy, Geir Frode</creatorcontrib><creatorcontrib>Emilsen, Elisabeth</creatorcontrib><creatorcontrib>Fleten, Karianne Giller</creatorcontrib><creatorcontrib>Ree, Anne Hansen</creatorcontrib><creatorcontrib>Flatmark, Kjersti</creatorcontrib><creatorcontrib>Gullestad, Hans Petter</creatorcontrib><creatorcontrib>Hermann, Robert</creatorcontrib><creatorcontrib>Ryder, Truls</creatorcontrib><creatorcontrib>Wernhoff, Patrik</creatorcontrib><creatorcontrib>Mælandsmo, Gunhild Mari</creatorcontrib><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flørenes, Vivi Ann</au><au>Flem-Karlsen, Karine</au><au>McFadden, Erin</au><au>Bergheim, Inger Riise</au><au>Nygaard, Vigdis</au><au>Nygård, Vegard Mokleiv</au><au>Farstad, Inger Nina</au><au>Øy, Geir Frode</au><au>Emilsen, Elisabeth</au><au>Fleten, Karianne Giller</au><au>Ree, Anne Hansen</au><au>Flatmark, Kjersti</au><au>Gullestad, Hans Petter</au><au>Hermann, Robert</au><au>Ryder, Truls</au><au>Wernhoff, Patrik</au><au>Mælandsmo, Gunhild Mari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases</atitle><jtitle>Translational oncology</jtitle><date>2019</date><risdate>2019</risdate><issn>1936-5233</issn><eissn>1936-5233</eissn><abstract>Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate therapy response. A strong association between Vemurafenib response and BRAF mutation status was achieved (P &lt; .0001), while enhanced viability was seen in some NRAS mutated tumors. BRAF and NRAS mutated tumors responded comparably to the MEK inhibitor Cobimetinib. Based on the ex vivo results, two tumors diagnosed as BRAF wild-type by routine pathology examinations had to be re-evaluated; one was subsequently found to have a complex V600E mutation, the other a double BRAF mutation (V600E/K601 N). No BRAF inhibitor resistance mechanisms were identified, but PIK3CA and NF1 mutations were identified in two highly responsive tumors. Concordance between ex vivo drug responses using tissue from PDXs and corresponding patient tumors demonstrate that PDX models represent an indefinite source of tumor material that may allow ex vivo evaluation of numerous drugs and combinations, as well as studies of underlying molecular mechanisms. In conclusion, we have established a rapid and low cost ex vivo drug efficacy assay applicable on tumor tissue from patient biopsies. The 3D/spheroid format, limiting the influence from normal adjacent cells and allowing assessment of drug sensitivity to numerous drugs in one week, confirms its potential as a supplement to guide clinical decision, in particular in identifying non-responding patients.</abstract><pub>Translational Oncology, University of Michigan Medical Center, Ann Arbor, MI</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-5233
ispartof Translational oncology, 2019
issn 1936-5233
1936-5233
language nor
recordid cdi_cristin_nora_10852_73986
source Open Access: PubMed Central; NORA - Norwegian Open Research Archives; ScienceDirect (Online service)
title A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A27%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-cristin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Three-dimensional%20Ex%20Vivo%20Viability%20Assay%20Reveals%20a%20Strong%20Correlation%20Between%20Response%20to%20Targeted%20Inhibitors%20and%20Mutation%20Status%20in%20Melanoma%20Lymph%20Node%20Metastases&rft.jtitle=Translational%20oncology&rft.au=Fl%C3%B8renes,%20Vivi%20Ann&rft.date=2019&rft.issn=1936-5233&rft.eissn=1936-5233&rft_id=info:doi/&rft_dat=%3Ccristin%3E10852_73986%3C/cristin%3E%3Cgrp_id%3Ecdi_FETCH-cristin_nora_10852_739863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true